공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

단장증후군 시장 : 성장, 동향, 예측

Short Bowel Syndrome Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 922071
페이지 정보 영문
가격
US $ 4,250 ₩ 4,793,000 PDF (Single User License)
US $ 4,750 ₩ 5,357,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,766,000 PDF (Site License)
US $ 7,500 ₩ 8,458,000 PDF (Corporate License)


단장증후군 시장 : 성장, 동향, 예측 Short Bowel Syndrome Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 단장증후군(Short Bowel Syndrome) 시장을 조사했으며, 시장의 개요, 종류, 지역별 시장 동향, 시장 규모의 추이와 예측, 시장 촉진·저해요인 및 시장 기회 분석, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 조사 성과
  • 조사의 전제조건
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 성장 촉진요인
  • 성장 저해요인
  • Porter's Five Forces 분석
    • 신규 진출의 위협
    • 소비자의 교섭력
    • 공급업체의 교섭력
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계

제5장 시장 세분화

  • 약물 클래스
    • GLP-2
    • 성장호르몬
    • 글루타민
    • 기타
  • 유통경로
    • 병원 약국
    • 소매 약국
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동·아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • TAKEDA Inc
    • Naia Pharmaceuticals Inc
    • OxThera Inc
    • VectivBio AG
    • Nutrinia Inc
    • Merck KGaA
    • GlyPharma Therapeutics
    • Sancilio & Company
    • Ardelyx Inc
    • Zealand Pharma

제7장 시장 기회 및 향후 전망

KSA 20.03.13

The Short Bowel Syndrome (SBS) Market studied was anticipated to grow with a CAGR of nearly 29.8%, during the forecast period. The major factors attributing to the growth of the SBS market are rise in global prevalence of GI disorders like volvulus, Inflammatory bowel disease (IBD), in particular, Crohn's disease (CD), which predisposes patients to development of SBS and mesenteric ischemia are the most common causes for SBS among all the age groups which demand the necessity of the treatment.

Additionally, the increased awareness programs led by several associations like the Association of gastrointestinal motility, Oley Foundation and the SBS Cure Project coupled with rising in the government health care expenditure are likely to drive the market growth over the forecast period.

Key Market Trends

GLP-2 Drug Therapy by Drug Class is Expected to Hold the Largest Market Share During the Forecast Period

The GLP-2 drug treatment accounts for the major market share throughout the forecast period. The dominance is due to the only products available for treatment with the brand names Gattex and Revestive, introduced by Takeda which were approved for sales in both the US and Europe respectively. Also, the patent exclusivity of GLP-2 drug is anticipated to contribute to its significant share in the revenue of the global short bowel syndrome market.

By distribution channels, hospital pharmacies are accounted for the highest market share due to the rapid implementation of therapy due to a huge patient pool. Also, the preference by the patients due to unaffordability and higher expensive parenteral nutrition along with prescription products contribute to a major share in the global short bowel syndrome market.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall Short Bowel Syndrome Market throughout the forecast period. This dominance is mainly due to the revenue generated by the Gattex, the only glucagon-like peptide-2 (GLP-2) analog approved that improves intestinal absorption in patients with SBS in the U.S. Also, rise in the sedentary lifestyle that led no time to focus on nutritious and healthy food with increased consumption of unhealthy and junk food, resultant intestinal disorders are a major factor that drives the market growth in the region.

The Asia Pacific is anticipated to grow at the fastest rate during the forecast period due to the huge patient pool in China and India, and the uncontrolled consumption of antibiotics in India. Also, the research activities and investments on R&D in the region are estimated to fuel the growth of the SBS market in the Asia Pacific and attribute to a significant share in global market.

Competitive Landscape

The global short bowel syndrome market is moderately competitive and consists of several prominent industry players. Some prominent players are making partnerships and acquiring the blockbuster products in the market, other companies and expanding their market position globally. For instance, Takeda acquired the Shire, to expanding its geographic footprint and to be a leader in providing targeted treatments in gastroenterology, the leading companies in gastroenterology (GI) and neuroscience. While other key players are focusing on distributing and manufacturing of over-the-counter dietary supplements. Whereas, some companies such as Naia Pharmaceuticals SBS, Micelle BioPharma, Inc. are having new products in their pipeline. Some of the companies which are currently dominating the market are TAKEDA Inc, Naia Pharmaceuticals Inc, VectivBio AG, OxThera Inc, and Nutrinia Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Prevalence of Short Bowel Syndrome and Awareness Programs by Non-Profit Organizations
    • 4.2.2 Rising Efforts in the Launch of Effective Treatments and Awareness Programs by Non-Profit Organizations
  • 4.3 Market Restraints
    • 4.3.1 Lack of Availability of the Approved Drugs in Developing Countries
    • 4.3.2 Lethal Adverse Complications like Colonic Cancer, Polyps along with Common Side Effects Associated with the Medication
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 GLP-2
    • 5.1.2 Growth Hormone
    • 5.1.3 Glutamine
    • 5.1.4 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Takeda Pharmaceutical Company Limited
    • 6.1.2 OxThera Inc.
    • 6.1.3 VectivBio AG
    • 6.1.4 Nutrinia
    • 6.1.5 Merck KGaA
    • 6.1.6 Pfizer Inc
    • 6.1.7 Ardelyx
    • 6.1.8 Zealand Pharma
    • 6.1.9 Nestle S.A.,

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q